Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), has announced the closing of a US$95 million Series C financing. Proceeds from the financing will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1 11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs. The financing was led by Goldman Sachs Alternatives. Latham & Watkins LLP represented Goldman Sachs in the offering with an Emerging Companies & Growth team led by Bay Area partner Saad Khanani, with associates Omar Ammash and Jay Trewn. Advice was also provided on FDA regulatory matters by Washington, D.C. counsel Chad Jennings; on intellectual property matters by Bay Area partner Judith Hasko, with associate Billy Wu; and on tax matters by Bay Area partner Grace Lee.~~